Tempus AI (TEM) Stock Surges on Expanded Gilead Partnership for Oncology Data Platform

Tempus AI's stock surged following an expanded partnership with Gilead Sciences for oncology data analytics. The company reported a 111% jump in diagnostics revenue with a contract backlog exceeding $1.1 billion, signaling strong commercial traction in the healthcare AI sector.